Cobra Biomanufacturing in agreement with the International Aids Vaccine Initiative (IAVI) and GlaxoSmithKline Biologicals for process development and manufacturing of two HIV vaccine candidates
The programme is in support of a previously announced collaboration between IAVI and GSK.
The vaccine candidates incorporate non-human primate adenovirus vectors.
Leveraging Cobra's expertise in adenovirus manufacture and related process development expertise, the work will be performed at Cobra's Oxford and Keele facilities.
Commenting on the contract, David Thatcher, CEO at Cobra, said: "We are very pleased to have been awarded this new manufacturing contract by two such renowned organisations at the forefront of Aids clinical research".
"It validates our manufacturing expertise with virus products and will contribute significantly to building our revenue stream over 2006 and 2007." The non-human primate adenovirus vector technology was derived from research conducted by scientists at the University of Pennsylvania.
The technology is owned by the University and is exclusively licensed to GSK.
Financial terms of the agreement were not disclosed.
